MicroRNA profiles as predictive markers of response to azacitidine therapy in myelodysplastic syndromes and acute myeloid leukemia

• DOI: 10.3233/cbm-171029
• Publication Date: 2018-04-03T16:13:30Z
• Authors: Zdenek Krejcik; Monika Belickova; Andrea Hrustincova; Hana Votavova; Anna Jonasova; Jaroslav Cermak; Jan E. Dyr; Michaela Dostalov...
• Keywords: Azacitidine; Decitabine

BACKGROUND: Azacitidine (AZA) is a nucleoside analog used for treatment of myelodysplasia and the prediction AZA responsiveness important therapy management. METHODS: Using microarrays reverse-transcription quantitative-PCR, we analyzed microRNA (miRNA) expression in bone marrow C D34+ cells 27 patients with higher-risk myelodysplastic syndromes or acute myeloid leukemia myelodysplasia-related changes before during treatment. RESULTS: At baseline, found that future overall response rate was significantly higher upregulated miR-17-3p downregulated miR-100-5p miR-133b. Importantly, high level at baseline associated shorter survival (HR = 4.066, P= 0.008). After treatment, observed deregulation 30 miRNAs responders (including downregulation miR-10b-5p, miR-15a-5p/b-5p, miR-24-3p, miR-148b-3p), while their levels remained unchanged non-responders. CONCLUSIONS: Our study demonstrates non-responders have distinct miRNA patterns specific may predict efficacy